<b>Results:</b> Our findings show that a <i>KLF4</i> genomic variant (rs2236599) is associated with HU treatment efficacy in sickle cell disease/β-thalassemia compound heterozygous patients and two <i>KLF10</i> genomic variants (rs980112, rs3191333) are associated with persistent HbF levels in NTDT patients.
<b>Results:</b> Our findings show that a <i>KLF4</i> genomic variant (rs2236599) is associated with HU treatment efficacy in sickle cell disease/β-thalassemia compound heterozygous patients and two <i>KLF10</i> genomic variants (rs980112, rs3191333) are associated with persistent HbF levels in NTDT patients.
<b>Results:</b> Our findings show that a <i>KLF4</i> genomic variant (rs2236599) is associated with HU treatment efficacy in sickle cell disease/β-thalassemia compound heterozygous patients and two <i>KLF10</i> genomic variants (rs980112, rs3191333) are associated with persistent HbF levels in NTDT patients.
Generation of an induced pluripotent stem cell line (CSC-44) from a Parkinson's disease patient carrying a compound heterozygous mutation (c.823C>T and EX6 del) in the PARK2 gene.